Sun Pharmaceutical Industries Limited — Credit Ratings, 07-05-2026: Credit Rating

Sun Pharma: CRISIL has reaffirmed 'Crisil AAA' on long-term bank facilities, but placed it on 'Rating Watch with Developing Implications' due to the Organon acquisition. Short-term facilities and commercial paper remain 'Crisil A1+'. ICRA also reaffirmed 'ICRA]AAA(Stable)' for long-term facilities and '[ICRA]A1+' for short-term, maintaining a stable outlook after noting the acquisition.